Cargando…
Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. Currently available therapies are symptomatic but do not alter underlying disease progression. Immunotherapeutic approaches such as anti Aβ peptide active vaccination trials have had limited success to date. Intravenous immunobl...
Autores principales: | Kayed, Rakez, Jackson, George R., Estes, D. Mark, Barrett, Alan D.T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663607/ https://www.ncbi.nlm.nih.gov/pubmed/23861639 http://dx.doi.org/10.4137/JCNSD.S5018 |
Ejemplares similares
-
Infectious etiology and amyloidosis in Alzheimer's disease: The puzzle continues
por: Kayed, Rakez
Publicado: (2021) -
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
por: Bittar, Alice, et al.
Publicado: (2018) -
Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013) -
Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits
por: Krishnan, Balaji, et al.
Publicado: (2018) -
Intravenous immunoglobulin for the treatment of Alzheimer’s disease: current evidence and considerations
por: Schindowski, Christina, et al.
Publicado: (2014)